Found: 18
Select item for more details and to access through your institution.
Therapeutic Advances in Advanced Basal Cell Carcinoma.
- Published in:
- Cancers, 2024, v. 16, n. 17, p. 3075, doi. 10.3390/cancers16173075
- By:
- Publication type:
- Article
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 1, p. 182, doi. 10.1007/s10637-020-01000-6
- By:
- Publication type:
- Article
Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.592202
- By:
- Publication type:
- Article
Phase Ib Study of Atezolizumab Plus Interferon-β with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.
- Published in:
- Current Oncology, 2021, v. 28, n. 6, p. 5466, doi. 10.3390/curroncol28060455
- By:
- Publication type:
- Article
The attitude of Canadian university students toward a behavior-based blood donor health assessment questionnaire.
- Published in:
- Transfusion, 2011, v. 51, n. 4, p. 742, doi. 10.1111/j.1537-2995.2010.02951.x
- By:
- Publication type:
- Article
Impact of early detection on cancer curability: A modified Delphi panel study.
- Published in:
- PLoS ONE, 2022, v. 17, n. 12, p. 1, doi. 10.1371/journal.pone.0279227
- By:
- Publication type:
- Article
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Cardiotoxicity of Targeted Agents in Oncology: A Medical Oncology Perspective.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 24, p. 7259, doi. 10.3390/jcm11247259
- By:
- Publication type:
- Article
Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion.
- Published in:
- Case Reports in Oncological Medicine, 2015, p. 1, doi. 10.1155/2015/893694
- By:
- Publication type:
- Article
Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
- Published in:
- International Journal of Cancer, 2021, v. 149, n. 2, p. 403, doi. 10.1002/ijc.33556
- By:
- Publication type:
- Article
Implementing a Tailored Psychosocial Distress Screening Protocol in a Head and Neck Cancer Program.
- Published in:
- Laryngoscope, 2022, v. 132, n. 8, p. 1600, doi. 10.1002/lary.30000
- By:
- Publication type:
- Article
Molecular characterization of the human gene encoding an abundant 61 kDa protein specific to the retinal pigment epithelium.
- Published in:
- Human Molecular Genetics, 1995, v. 4, n. 4, p. 641
- By:
- Publication type:
- Article
Prediction of Clinical Deterioration in Hospitalized Adult Patients with Hematologic Malignancies Using a Neural Network Model.
- Published in:
- PLoS ONE, 2016, v. 11, n. 8, p. 1, doi. 10.1371/journal.pone.0161401
- By:
- Publication type:
- Article
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
- Published in:
- Molecular Cancer, 2015, v. 14, n. 1, p. 1, doi. 10.1186/s12943-015-0293-5
- By:
- Publication type:
- Article
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma.
- Published in:
- Molecular Cancer, 2014, v. 13, p. 1, doi. 10.1186/1476-4598-13-194
- By:
- Publication type:
- Article